Pulmonary Infections in the Immunocompromised Host
Yildirim I, Gibson J, Danziger-Isakov L. Pulmonary Infections in the Immunocompromised Host. Respiratory Medicine 2020, 235-252. DOI: 10.1007/978-3-030-54924-4_20.Peer-Reviewed Original ResearchPulmonary infectionHematopoietic stem cell transplantationCurrent immune statusSolid organ transplantationStem cell transplantationPrimary immunodeficiency patientsImmunocompromised childrenCommon complicationImmune compromiseImmunocompromised hostPulmonary diseaseBronchoalveolar lavageImaging findingsClinical symptomsCell transplantationImmune statusImmunodeficiency patientsInvasive studiesOrgan transplantationHigh riskCommon pathogensPatientsInfectionExposure historyTransplantationInitial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole
Bernardo V, Miles A, Fernandez AJ, Liverman R, Tippett A, Yildirim I. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole. Pediatric Transplantation 2020, 24: e13777. PMID: 32639095, DOI: 10.1111/petr.13777.Peer-Reviewed Original ResearchConceptsYears of ageMedian daily doseTrough concentrationsDaily dosePlasma concentrationsYoung adultsPlasma trough concentrationsSerum posaconazole concentrationsInvasive fungal diseaseTherapeutic plasma concentrationsDelayed-release tabletsIntravenous posaconazolePosaconazole dosingImmunocompromised childrenPatients 13Optimal dosingBroad-spectrum antifungalsAdolescent patientsPosaconazole concentrationsHigher dosingPatientsBody weightGrade 1ProphylaxisDosing